Ling I T, Ogun S A, Momin P, Richards R L, Garçon N, Cohen J, Ballou W R, Holder A A
National Institute for Medical Research, Mill Hill, London, UK.
Vaccine. 1997 Oct;15(14):1562-7. doi: 10.1016/s0264-410x(97)00076-5.
Mice vaccinated with a recombinant protein containing the two EGF-like modules of Plasmodium yoelii merozoite surface protein-1 in liposomes or combined with the formulations SBAS2.1 and SBAS2, were protected against a lethal malaria infection. The protection achieved with these adjuvants developed for clinical use was as good as or better than that achieved with Freund's adjuvant. A parasite-specific response was needed for protection. Analysis of the immunoglobulin sub-class response showed that MSP-1-specific IgG1, and to a lesser extent IgG2a and IgG2b, were induced, suggesting that these antibodies were important for protection. Mice passively immunized with serum or purified IgG from vaccinated mice had delayed onset of parasitemia and were able to control the infection.
用含有约氏疟原虫裂殖子表面蛋白-1的两个表皮生长因子样模块的重组蛋白在脂质体中或与制剂SBAS2.1和SBAS2联合接种的小鼠，可免受致死性疟疾感染。这些用于临床的佐剂所实现的保护效果与弗氏佐剂相当或更好。保护需要寄生虫特异性反应。对免疫球蛋白亚类反应的分析表明，诱导了MSP-1特异性IgG1，以及程度较轻的IgG2a和IgG2b，表明这些抗体对保护很重要。用接种小鼠的血清或纯化IgG进行被动免疫的小鼠，其寄生虫血症的发作延迟，并且能够控制感染。
